University of Nebraska Medical Center


The Pharmacy and Therapeutics Committee has approved the addition of Peramivir to the inpatient formulary with restriction to ID use only. Peramivir is an intravenous neuraminidase inhibitor that is FDA-approved for the treatment of acute uncomplicated influenza in adults 18 years and older. Prior to its approval, the FDA had authorized emergency use of peramivir to treat certain hospitalized patients with known or suspected 2009 H1N1 influenza.

Criteria for Use:

Peramivir is restricted for use to ID only. In addition, its use should be limited to patients who are unable to take oseltamivir due to an inability to ingest or absorb oral medication. Examples of these situations would include severe GVHD or mucositis, ileus, or patient intubated with no enteral access. Once medications may be given enterally, patients should be changed to oseltamivir to complete therapy as oseltamivir has shown to be well absorbed even when provided through a nasogastric tube.

Further details on dosing, renal adjustment, efficicay data, etc. are available at the link below.

Peramivir Guidance and Drug Review